Moderna and Merck cancer vaccine met key endpoints in melanoma trial

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

MADRID — A personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% compared to a standard treatment, according to a large clinical trial conducted by the drugmakers Moderna and Merck.

The results are an important advance for the treatment of melanoma, oncologists said, because patients lived significantly longer without their cancer returning.

The success of the Moderna-Merck vaccine, intismeran autogene, may also usher in a new wave of treatments for other types of cancer, though experts are debating how broadly applicable the technology could be. The medicine is an individualized therapy that attacks the unique mutations, called neoantigens, found in a patient’s tumor. The approach is made possible by the same mRNA technology that led to the rapid development of vaccines against Covid-19.

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

Understand how science, health policy, and medicine shape the world every day

Your data will be processed in accordance with our Privacy Policy and Terms of Service. You may opt out of receiving STAT communications at any time.

The Readout

The Readout October 22, 2026

STAT Plus: Will the Treasury restrict U.S. investment in the Chinese biotech sector?

By Meghana Keshavan and John Wilkerson

Biotech

Biotech October 22, 2026

STAT Plus: What to expect from the Moderna-Merck cancer vaccine data reveal

By Adam Feuerstein

AI Prognosis

AI Prognosis October 21, 2026

STAT Plus: What’s the deal with Isomorphic Labs?

By Brittany Trang